• NovoSorb BTM creates a vascular bed to support transplanted islet cells
• Islet cells can be easily monitored and retrieved from the intracutaneous site
• Two of three patients showed positive c-peptide levels at 3 months post-transplant

PolyNovo has announced positive results from a proof-of-concept study using its NovoSorb BTM technology to support the transplantation of human pancreatic islet cells for the treatment of Type 1 diabetes. The study, led by Professor Toby Coates, involved three participants with long-standing Type 1 diabetes who received islet cell transplants after a kidney transplant. Prior to the islet cell transplant, PolyNovo's NovoSorb BTM was implanted in the participants' inner biceps, creating a vascular bed to support the transplanted cells. This intracutaneous transplant site allows the islet cells to be easily monitored and retrieved, unlike the standard liver transplant site. The results showed that two of the three participants had positive c-peptide levels at 3 months post-transplant, indicating the islet cells were functioning. One of these participants has maintained long-term graft function out to 2.5 years. All participants showed improvements in glycemic control over the 12-month study period. PolyNovo's Chairman, David Williams, stated that these results are 'very exciting' and could create a new business opportunity for PolyNovo in the cell therapy market, which is estimated to be worth $34 billion by 2034. PolyNovo and its research partners, Professors Coates and Greenwood, are now in discussions to accelerate the development of PolyNovo's technology for use in cell therapies.

PolyNovo anticipates that its NovoSorb BTM technology could play a major role in the cell therapy market, which is estimated to be worth USD $34 Billion by 2034.

PolyNovo and its research partners are in discussions to accelerate the development of PolyNovo's NovoSorb BTM technology for use in cell therapies, building on the promising results from the proof-of-concept study.